Phase 2 N=30 Tau Imaging of Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
CTE · TBI (Traumatic Brain Injury)
Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02
N/A N=1,485 Career Enhancement Training Study (USAF)
Suicidal Ideation
Primary: Mean Computerized Adaptive Testing for Suicide Severity — 10.76; 12.12 units on a scale — p=.062
N/A N=100 CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Phase 2 N=41 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959
N/A N=494 Comparative Effectiveness Study of Transthoracic and Transesophageal Echocardiography in Stroke
Stroke, Acute
Primary: Number of Participants With Diagnostic Findings That Lead to a Change in Acute Treatment or Treatment for Secondary Prevention — 64; 390; 86; 368 Participants
N/A N=150 Chronic Total Occlusion Percutaneous Coronary Intervention Study
Chronic Total Occlusion · Ischemic Heart Disease · Chronic Total Occlusion of Coronary Artery
Primary: Number of Participants With Procedure Success — 121 Participants
N/A N=6 Cranial Electrotherapy Stimulation (CES) Therapy
TBI · Anxiety · PTSD
Primary: PCL-5 (Post Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders) for Use in Treating PTSD Symptoms — 44.25 scores on a scale
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
N/A N=320 Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.
Colorectal Cancer Screening
Primary: Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy — 34; 11 Participants
Phase 3 N=125 Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale, for DSM-IV (CAPS IV) — -15.97; -11.22 units on a scale — p=> .05
N/A N=64 The PROTEMBO C Trial
Valvular Heart Disease
Primary: Rate of Participants With MACCE Events — 3 Participants
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
N/A N=379 Augmenting Cognitive Training In Older Adults
Aging
Primary: Improvement in Cognitive Ability. — 4.7; 4.5 units on a scale — p=<0.05
N/A N=155 EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1
Eye-tracking
Primary: Changes in the Eye-tracking Score Before and After Practice or Game: Phase Error — -0.6; -0.8 Degrees
N/A N=637 Transforming Research and Clinical Knowledge in TBI Pilot
Traumatic Brain Injury
Primary: Glasgow Outcome Scale Extended (GOSE) — 7; 5 Glasgow Outcome Scale Extended (GOSE)
N/A N=100 The Cyclical Lower-extremity Exercise for Parkinson's Trial
Parkinson's Disease
Primary: MDS-UPDRS Motor III Score — -4.8; -4.9; 1.8 change in MDS- UPDRS III score
N/A N=12 Comparing MRI to CT on Pediatric Craniosynostosis.
Craniosynostosis
Primary: Number of Participants With 90% or Greater Concordance Between ZTE and CT Imaging Diagnosis — 9 Participants
N/A N=102 Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Primary: Time to Imaging — 28.1; 7.1 hours
N/A N=150 TeamTRACS Pilot (CTSI)
Teamwork · Implementation
Primary: Change in Teamwork Knowledge From Baseline to 3-month Follow-up — 75.60; 74.72; 80.00; 75.00 percentage correct answers — p=.03
N/A N=21 Assessment and Treatment of Cognitive Functioning Deficits in Veterans With PTSD
Posttraumatic Stress Disorder
Primary: Prospective-Retrospective Memory Questionnaire (PRMQ; Crawford et al., 2006) — 50.38; 38.5; 47.875; 42.5 score on a scale
Phase 3 N=1,000 Trial to Assess Chelation Therapy 2
Diabetes · Myocardial Infarction
Primary: Primary Composite Outcome — 85; 89; 90; 86 Participants
N/A N=75 Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging
Spinal Cord · Epidural
Primary: Number of Thoracic Spinal Segments Successfully Visualized With TEE — 12; 10 Thoracic segments
N/A N=55 The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
Carotid Artery Diseases · Carotid Atherosclerosis · Carotid Stenosis
Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants
N/A N=127 Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL
Thoracic Diseases
Primary: Number of Subjects With Procedural Technical Success — 123 Participants
Phase 2 N=153 A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Mild to Moderate Alzheimer's Disease
Primary: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) — 36; 42; 39; 19 Participants
N/A N=2,502 Carotid Revascularization Endarterectomy Versus Stenting Trial
Atherosclerosis · Stroke · Carotid Stenosis
Primary: Any Periprocedural Stroke, Myocardial Infarction, or Death During a 30-day Peri-procedural Period, and Postprocedural Ipsilateral Stroke Thereafter, up to 4-years…
Phase 2 N=16 Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants
N/A N=1,187 Telecommunication Enhanced Asthma Management
Asthma
Primary: Medication Adherence — .445; .355 Proportion of Days Covered